Sort
48,018 grants matching “immunotherapy”
IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTES
$520,632Warren S Pear · University Of Pennsylvania · T32 · FY2015 · CA
Metabolic Regulation ofPD-L1 in CD11c+ Cells
$520,593Cong Yan · Indiana University Indianapolis · R01 · FY2023 · CA
Metabolic Regulation ofPD-L1 in CD11c+ Cells
$520,593Cong Yan · Indiana University Indianapolis · R01 · FY2022 · CA
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer
$520,592Humam Kadara · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Novel Strategies for Precision T-cell Therapies
$520,564Steven C. Almo · Albert Einstein College Of Medicine, Inc · R01 · FY2017 · CA
Novel Strategies for Precision T-cell Therapies
$520,564Steven C. Almo · Albert Einstein College Of Medicine, Inc · R01 · FY2016 · CA
Novel Strategies for Precision T-cell Therapies
$520,564Steven C. Almo · Albert Einstein College Of Medicine · R01 · FY2020 · CA
Developing new therapeutic strategies for brain metastasis
$520,544Eva Hernando · New York University School Of Medicine · R01 · FY2024 · CA
PAG is a novel target in immunotherapy
$520,485Adam Mor · Columbia University Health Sciences · R01 · FY2022 · AI
Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.
$520,435Emily H Cheng · Sloan-Kettering Inst Can Research · U54 · FY2024 · CA
Breast Cancer Treatment with Antibody Targeted T Cells
$520,390Roger Williams Hospital · R01 · FY2004 · CA
IL-17-driven mechanisms for tumor progression and resistance to therapies
$520,309Thaddeus S Stappenbeck · Cleveland Clinic Lerner Com-Cwru · P01 · FY2025 · CA
IL-17-driven mechanisms for tumor progression and resistance to therapies
$520,309Xiaoxia Li · Cleveland Clinic Lerner Com-Cwru · P01 · FY2022 · CA
Administrative Core
$520,261Mauro Ferrari · Methodist Hospital Research Institute · U54 · FY2016 · CA
Functional and Therapeutic Significance of PLK4 in Melanoma
$520,204Nihal Ahmad · University Of Wisconsin-Madison · R01 · FY2024 · CA
Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation
$520,199Gabriel Oliveira Sawakuchi · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation
$520,199Gabriel Oliveira Sawakuchi · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Role of Telomere and telomerase In Human Lymphocyte Function and Aging
$520,160Nan-Ping Weng · National Institute On Aging · ZIA · FY2021 · AG
Canine Immuno Neurotherapeutics
$520,152M R Chambers · University Of Alabama At Birmingham · U01 · FY2020 · CA
Canine Immuno Neurotherapeutics
$520,152M R Chambers · University Of Alabama At Birmingham · U01 · FY2021 · CA
Strategies to predict and overcome resistance to cancer immunotherapy
$520,119Steven L Reiner · Columbia University Health Sciences · R01 · FY2024 · CA
Evaluation of treatment predictors reflecting beta-catenin activation in hepatocellular carcinoma
$520,008Sandi Alexander Kwee · Queen'S Medical Center · R01 · FY2021 · CA
Deciphering the molecular control of intratumoral dendritic cells
$519,902Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
INTRAVITAL IMAGING OF MELANOMA TUMORS FOR MECHANISM DISCOVERY AND PATIENT SURVEILLANCE AFTER CHECKPOINT BLOCKADE IMMUNOTHERAPY
$519,854University Of California Irvine · · FY2025 · Defense Health Agency
Targeted Therapy of B-cell Malignancies
$519,832David M Goldenberg · Ctr For Molecular Medicine/Immunology · P01 · FY2009 · CA